Streetbeat News

Products Services

ISPC

iSpecimen has upgraded its proprietary marketplace platform to streamline biospecimen matchmaking for researchers and providers at lower costs. The enhancement is expected to improve the efficiency of the platform and reduce costs for users.

Portfolio Pulse from Benzinga Newsdesk

August 16, 2023 | 11:34 am

ELEV

Elevation Oncology has announced that the first patient has been dosed in a Phase 1 trial of EO-3021, a treatment for patients with advanced unresectable or metastatic solid tumors.

Portfolio Pulse from Benzinga Newsdesk

August 16, 2023 | 11:31 am

SONN

Sonnet BioTherapeutics has announced that the FDA has accepted the company's IND for the SB221 clinical trial of SON-1010 combined with Atezolizumab in the US.

Portfolio Pulse from Benzinga Newsdesk

August 16, 2023 | 11:31 am

NVRO

Nevro has announced the publication of 24-month data from the SENZA Painful Diabetic Neuropathy trial of spinal cord stimulation. The new data shows that Nevro's SCS therapy provides highly effective, long-term relief for painful diabetic neuropathy.

Portfolio Pulse from Benzinga Newsdesk

August 16, 2023 | 11:26 am

PLUR

Pluri has published an article in the peer-reviewed journal Nature Bone Marrow Transplantation, demonstrating that PLX-R18 increases blood cell counts and reduces the need for transfusions in a Phase 1 study.

Portfolio Pulse from Benzinga Newsdesk

August 16, 2023 | 11:18 am

ELDN

Eledon Pharmaceuticals (NASDAQ:ELDN) has announced the dosing of the 10th patient in its ongoing Phase 1b trial evaluating tegoprubart in kidney transplant patients. The company will report interim clinical data from this study at the American Society of Nephrology (ASN) Kidney Week Annual Meeting in November 2023.

Portfolio Pulse from Benzinga Newsdesk

August 16, 2023 | 11:07 am

TELA

TELA Bio, Inc. (NASDAQ:TELA) has announced the US commercial launch of their product, OviTex PRS Long-Term Resorbable. The product is intended for implantation to reinforce soft tissue in patients requiring soft tissue repair or reinforcement in plastic and reconstructive surgery.

Portfolio Pulse from Benzinga Newsdesk

August 16, 2023 | 11:05 am

TNXP

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) has initiated a Phase 1 single ascending dose escalation study of TNX-1500 in healthy volunteers. The study aims to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of intravenous TNX-1500.

Portfolio Pulse from Benzinga Newsdesk

August 16, 2023 | 11:04 am

CSIQ

Canadian Solar's subsidiary, Recurrent Energy, has secured a 20-year tolling agreement with Arizona Public Service Company. The construction of Papago Storage is expected to begin in Q3 2024 and is planned to be operational by Q2 2025. Once operational, it will be the largest standalone energy storage project in Arizona.

Portfolio Pulse from Benzinga Newsdesk

August 16, 2023 | 11:04 am

BLUE

The FDA has confirmed that it will not schedule an Advisory Committee meeting for bluebird bio's Lovo-Cel gene therapy for Sickle Cell Disease. The agency had previously accepted the Lovo-Cel Biologics Licensing Application (BLA) for Priority Review and set a Prescription Drug User Fee Act (PDUFA) goal date of December 20, 2023.

Portfolio Pulse from Benzinga Newsdesk

August 16, 2023 | 11:02 am